BridgeBio is substantially improved the development of an new therapy for cardiac amyloidosis, utilizing Attruby. Preliminary trial data reveals promising improvements for patients affected by this severe illness. This effort highlights BridgeBio's commitment to treating significant healthcare requirements in a cardiology arena. Attruby… Read More